stockrowIDEXX Laboratories, Inc.
IDXX Healthcare Diagnostics & Research
IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.
- Revenue
- +9.86%
- EPS
- +17.3%
- Free cash flow
- +17.6%
- Total debt
- −28.6%
Quarter to September 2026, against a year earlier
Follow IDXX
Alert me
IDEXX Laboratories, Inc. (IDXX) EPS (diluted)
IDEXX Laboratories, Inc.'s EPS (diluted) for fiscal 2025 was $13.08, up 22.6% from $10.67 in fiscal 2024. Over the twelve months to 30 September 2026 it was $14.83. Over the past ten years it has ranged from $2.05 (fiscal 2015) to $13.08 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 3 consecutive fiscal years. IDEXX Laboratories, Inc. ranks 4th of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $13.08 | 22.59% |
| FY2024 | $10.67 | 6.06% |
| FY2023 | $10.06 | 25.28% |
| FY2022 | $8.03 | (6.63%) |
| FY2021 | $8.60 | 28.17% |
| FY2020 | $6.71 | 37.22% |
| FY2019 | $4.89 | 14.79% |
| FY2018 | $4.26 | 44.90% |
| FY2017 | $2.94 | 20.49% |
| FY2016 | $2.44 | 19.02% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $4.01 | (6.04%) |
| Jun 2026 | $4.27 | 23.05% |
| Mar 2026 | $3.47 | 12.66% |
| Dec 2025 | $3.08 | (9.41%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MTD Mettler-Toledo International, Inc. compare | $44.43 |
| IDXX IDEXX Laboratories, Inc. | $14.83 |
| LH Labcorp Holdings Inc. compare | $12.19 |
| DGX Quest Diagnostics Incorporated compare | $10.04 |
| IQV IQVIA Holdings Inc. compare | $8.24 |
| ILMN Illumina, Inc. compare | $5.81 |
| A Agilent Technologies, Inc. compare | $5.08 |
| WAT Waters Corporation compare | $2.33 |
| NTRA Natera, Inc. compare | −$1.14 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on IDXX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement